|
Aug 13
|
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
|
|
Aug 1
|
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
|
|
Jul 30
|
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
|
|
Jul 24
|
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
|
|
Jul 24
|
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
|
|
Jun 27
|
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
|
|
Feb 7
|
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
|